Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.
Gerhartz
H H
HH
Med. Dept. III, Klinikum Grosshadern, Munich University, FRG.
Visani
G
G
Delmer
A
A
Zwierzina
H
H
Ribeiro
M
M
Jacobs
A
A
Marcus
R
R
Baumelou
M
M
Fière
D
D
Labar
B
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003115:Colony-Stimulating Factors / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000628:therapy; D016032:Randomized Controlled Trials as Topic
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor